Autoimmune🦋

@autoimmuneaware.bsky.social

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project 🚩lack of uniform terminology and abbreviations = challenges in research and clinical practice 🏳️anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature academic.oup.com/rheumatology...

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project

ABSTRACTObjectives. The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinic

academic.oup.com

Prognostic insights from symptom clustering analysis in systemic lupus erythematosus 1️⃣ Articular/mucocutaneous ➡️better survival 2️⃣Severe phenotype with renal involvement ➡️ poor prognosis 3️⃣Mixed connective tissue disease-like features with anti-U1-RNP antibodies rmdopen.bmj.com/content/11/2...

Prognostic insights from symptom clustering analysis in systemic lupus erythematosus

Objective Systemic lupus erythematosus (SLE), a systemic autoimmune disease with heterogeneous severity, poses a challenge in classifying patients due to its dynamic phenotype. We therefore aimed to i...

rmdopen.bmj.com

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis 📌In patients with giant-cell arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo with a 52-week glucocorticoid taper www.nejm.org/doi/full/10....

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several...

nejm.org